Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pipeline Watch: A New Era

Scrip’s popular Pipeline Watch feature has been updated to provide you with more analysis

READ NOW


Featured Stories


Big Pharmas Trust To The Science In Zantac Lawsuits

Billions of dollars have been wiped off the value of big pharma stocks as the market finally woke up to widescale litigation concerning allegations of increased cancer risk associated with the use of ranitidine. Two companies, GSK and Sanofi, are confident that there is no link. 

Legal Issues Companies Safety

Daiichi Sankyo/AstraZeneca Get Two Lucky Breaks For Enhertu

The FDA granted accelerated approval for the small but significant HER2-mutated NSCLC indication, while the arbitrator in Seagen’s arbitration case ruled in Daiichi Sankyo’s favor.

Approvals Legal Issues Cancer

Valneva Confirms Step Back From COVID-19 Vaccine Development

The French firm has suspended the manufacturing of its COVID-19 vaccine, instead emphasizing its hopes in advanced Lyme disease and Chikungunya.

Coronavirus COVID-19 Vaccines Sales & Earnings

Asia Spotlight

China-US Tensions Rise Sharply On Pelosi Visit, Will Biotech Get Burned?

Where once there were promising prospects for cross-strait collaboration, biopharma firms in mainland China and Taiwan may now find themselves looking elsewhere for partners following a controversial visit to Taipei by US House Speaker Nancy Pelosi.

China Policy

More coverage from Scrip's team in Asia

Latest News

Scrip Podcast

Insights and perspectives on commercial, R&D,

deal-making and business strategy developments.

More Podcasts


Recent Tweets from Scrip


 

Infographics

Titans Of Pharma 2022: Johnson & Johnson Pays Highest Exec Compensation Again

Infographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.

Companies Leadership

COVID-19 Vaccine Pediatric Landscape In India - Biological E Scores, Zydus At Zero

India’s COVID-19 immunization focus has shifted to children as over 88% adults are fully vaccinated. However, Scrip’s examination of weekly data reveals the number of doses given to children are also dropping sharply off peaks. Meanwhile, Biological E is winning over others like Novavax in this segment while Zydus Lifesciences is yet to score

Commercial Coronavirus COVID-19

Challenging Alzheimer's: Korean Firms Forge Ahead In Multiple Modalities

Scrip takes an infographic look at where South Korea stands in the development of a wide-ranging set of drugs for Alzheimer’s disease and which companies are still in the challenging race.

South Korea Clinical Trials

Commercial Explore this Topic

Set Alert for Commercial

Latest From Commercial

Finance Watch: Karuna, Cerevel And Others Benefit From Improving Biotech Sentiment

Good news in the biopharma industry and the US economy gave public drug developers the boost they needed to raise cash, including Karuna’s $750m offering. Private company financings slowed during the second week of August, but Prellis and Vector BioPharma raised venture capital.

Financing Growth

Lupin Counts On Generic Spiriva Launch In Q4 To Turn US Tide

Even as it prepares for competition from an authorized generic, Lupin expects a launch of its generic to Boehringer’s blockbuster Spiriva in the fourth quarter of FY23. It hopes the launch will help its position in the US, where it has exited low margin products amid heightened competition, leading in turn to manufacturing job losses in India

Commercial Business Strategies

Asia Deal Watch: Hansoh, TiumBio Join Forces On Endometriosis Drug In Greater China

Plus deals involving Shionogi/ Grünenthal, CR Biopharma/ImmVira, Elevation Oncology/CSPC, Everest Medicines/TTY Biopharm and Dr. Reddy’s/Slayback

Deal Watch Asia Pacific

Anthos Takes On Pharma Giants In Factor XI Anticoagulation Space

CEO John Glasspool spoke with Scrip about why Anthos believes it has a good shot against big competitors in a market that is expected to generate blockbuster sales across multiple products.

Cardiovascular Innovation

Deal Watch: Gemini Goes Through Second Re-Invention Via Reverse Merger With Disc Medicine

Less than two year after going public by a SPAC merger, Gemini will reverse merge with hematology-focused Disc. Bristol Myers Squibb and GentiBio will join forces on Treg development for inflammatory bowel disorders.

Deal Watch Business Strategies

Merck Takes A New Shot At Alzheimer’s With Cerevance Deal

The major will use the biotech’s brain cell-focused platform technology to discover new targets for Alzheimer’s disease.

Deals Neurology
See All

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

Latest From Policy & Regulation

MaaT’s FDA Woes Highlight Rocky Regulatory Path For Microbiome-Based Therapies

The French firm's lead microbiome therapy has been on clinical hold in the US for a year and continuing concerns about MaaT's 'pooling' approach (mixing donations from multiple donors) suggests the wait to restart trials will not be a short one.

Clinical Trials Infectious Diseases

Lost In Translation? New Zoonotic Virus Naming Gets China's Largest Physician Platform In Trouble

China's largest physician portal DXY has been banned from posting on a major social media platform after naming a new zoonotic virus after the place where it originated.

Coronavirus COVID-19 China

Patent Settlements and Medicare Negotiation: What Leverage Does Pharma Have To ‘Game’ Price Reform?

Brand drug companies might be able to use patent settlements with generic and biosimilar makers to get out of the drug price negotiations that will be created under the US legislation nearing enactment, but sponsors could run into regulatory and antitrust obstacles.

Legislation Pricing Debate
See All

Research & Development

Set Alert for Research & Development

Latest From Research & Development

Aptinyx Appears To Be Moving On From Pain With Fibromyalgia Miss

Lead candidate NYX-2925 has failed a pair of Phase IIb studies in diabetic peripheral neuropathy and now one in fibromyalgia, leaving Aptinyx’s likely last hopes in neuropsychiatric indications.

Clinical Trials Business Strategies

Frontier Bets $52m On Potential Rival To Gilead's Veklury

Frontier Biotechnologies is seeking to enroll roughly 1,200 hospitalized COVID patients in an international Phase II/III clinical trial to evaluate its bofutrelvir (FB2001) in competition with Gilead’s Veklury.

China Clinical Trials

From Treatment To Prevention To A Cure: An Interview With Gilead’s HIV R&D Leaders

Gilead execs Jared Baeten and Tomas Cihlar talk to Scrip about how the company, still the leader in HIV, is working toward less-frequent dosing, providing PrEP for broader populations and maybe finding a cure for HIV infection.

Business Strategies Clinical Trials
See All
UsernamePublicRestriction

Register